# Anchor a TGF-beta trap in the tumour stroma so it cannot act everywhere

Source: https://onco.cc/ideas/idea-bio2-tumour-anchored-tgfbeta-trap/  
OnCo record `idea-bio2-tumour-anchored-tgfbeta-trap` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TGF-beta is a signal that keeps immune cells out of tumours, but blocking it throughout the body caused bleeding and heart toxicity and sank bintrafusp alfa. Tethering the blocker to tumour stroma with a FAP anchor, a collagen-binding domain or a protease-activated mask could give the benefit without the harm.

## Summary

Systemic TGF-beta blockade, including the PD-L1-TGF-beta trap bintrafusp alfa, failed largely on a narrow therapeutic index with bleeding and cardiac toxicity. Localisation strategies (a FAP-anchored trap, a collagen-binding domain fusion, or a protease-activated masked format) restrict activity to stroma-rich tumour tissue, and masked antibody formats are already in clinical trials.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A stroma-anchored TGF-beta trap achieves at least tenfold higher tumour-to-plasma target engagement than an unanchored trap and increases T-cell penetration into the tumour core without cardiovascular toxicity.
- Rationale: TGF-beta is one of the best-validated barriers to T-cell infiltration in human tumours, notably in urothelial cancer where a stromal TGF-beta signature predicts checkpoint failure. The failure of systemic agents is an index problem, and localisation is the standard fix.
- Proposed test: Preclinical head-to-head of anchored versus systemic trap for exposure ratio and toxicity, then a phase 1 with paired biopsies measuring stromal phospho-SMAD2 suppression and CD8 distribution relative to stroma.
- Maturity: preclinical-evidence
- Actor: industry

## Sources

- Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019): https://doi.org/10.1001/jamanetworkopen.2019.2535

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Masked / conditionally active ADC](https://onco.cc/technologies/masked-adc/)
- targets: [FAP](https://onco.cc/targets/fap/), [PD-L1](https://onco.cc/targets/pdl1/)
- terms: [Desmoplasia (tumour stroma)](https://onco.cc/terms/desmoplasia/), [Hot vs cold tumours](https://onco.cc/terms/cold-vs-hot/)
- bottlenecks: [Cold tumours and the immunosuppressive microenvironment](https://onco.cc/bottlenecks/b-tme-immunosuppression/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/)
- key papers: [Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs](https://onco.cc/key-papers/paper-haslam-jama-netw-open/), [Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway](https://onco.cc/key-papers/paper-pd-l1-urothelial-trends-mol-med-2015/), [PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy](https://onco.cc/key-papers/paper-pd-l1-urothelial-mol-cancer-ther-2015/), [PD-L1 expression in human cancers and its association with clinical outcomes](https://onco.cc/key-papers/paper-pd-l1-urothelial-onco-targets-ther-2016/)

---
JSON: https://onco.cc/api/v1/entities/idea-bio2-tumour-anchored-tgfbeta-trap.json